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|  Introduction
Cannabis is the drug most often mentioned in reports of drug law offences in Europe. In 2014, 
the drug accounted for 57 % of an overall estimate of 1.6 million offences (EMCDDA, 2016). 
Cannabis is also Europe’s most commonly used illicit drug. It is estimated that at least one in 
every eight young adults (aged 15–34 years) used cannabis in the last year across the European 
Union. At the national level, these rates range from less than 1 % to over 20 % of young adults. 
The most recent data suggest that 1 % of the adult population (aged 15–64 years) of the 
European Union and Norway, or about 3 million individuals, are smoking cannabis on a daily or 
near-daily basis. The trends in use also vary between countries. In surveys since around 2005, 
Germany, Spain and the United Kingdom have shown decreasing or stable trends in reported 
use, while upward trends can be observed in Bulgaria, France and three of the Nordic countries 
(Denmark, Finland and Sweden).
A renewed debate about the laws prohibiting or permitting cannabis use and supply around the 
world has been fuelled by the legalisation of supply and use of cannabis for ‘recreational’ 
purposes in some US states and Uruguay since 2012. Proposals to legalise the drug have raised 
concerns they may lead to increases in cannabis use and related harms, and questions about 
the ways in which cannabis for non-medical purposes could be regulated to mitigate these 
concerns. In the European Union, a system of limited distribution has evolved in the Netherlands 
since the 1970s, and this has seen further developments in the last few years. The advantages 
and disadvantages of these regulated systems are being closely observed. The model of 
‘cannabis social clubs’ has been increasingly mentioned in drug policy debates. Its advocates 
argue that the decision to not prosecute individuals for cannabis use in some countries can also 
be applied to registered groups of individuals, in order to permit a closed system of cannabis 
production and distribution. At present, the model is rejected by national authorities in Europe.
Throughout Europe there is media and public discourse on the issue of changing cannabis laws. 
However, national administrations are concerned about the public health impact of cannabis use 
and generally oppose the decriminalisation or legalisation of cannabis for recreational use. 
Nonetheless, cannabis laws and the medical and scientific research that informs policy-making 
can be regarded as entering a period of change, the direction of which is still unclear.
It is with this background in mind that the EMCDDA has decided to produce this report. 
Incorporating and building on earlier EMCDDA work (see Resources, page 30), the present study 
outlines the legislation relating to cannabis around the European Union (with a focus on 
‘recreational’ use, rather than production and use for medical or industrial purposes). Written for 
a broad audience, the report aims to give brief answers to some of the more frequently asked 
questions raised in the discussions about cannabis legislation. These have been grouped into 
four parts:
1. What is cannabis and what are countries’ obligations to control it?
2. What do the laws and associated guidelines say?
3. What happens to cannabis offenders in practice?
4. Where is cannabis legislation going?
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Cannabis control in Europe: at a glance
International law obliges control of cannabis plants and products. There may be permissions 
for medical and industrial use.
Cannabis-based medicines may have EU or national authorisation. No country officially 
authorises cannabis smoking for medical purposes.
There is little harmonisation among EU Member States in the laws penalising unauthorised 
cannabis use or supply. Some countries legally treat cannabis like other drugs; in others, 
penalties vary according to the drug or offence involved.
The penalties available for cannabis supply vary considerably, but only comparing maximum 
penalties in the laws gives a misleading picture.
Evidence suggests that police tend to register cannabis use offences, rather than overlooking 
them as ‘minor’. In a few countries there can be a rehabilitative response such as counselling 
or treatment.
Some terms often used for policy comparison need to be clearly defined, complicating 
comparisons; the terms ‘decriminalisation’ and ‘personal use’ have varied interpretations. 
While all countries in Europe treat possession for personal use as an offence, over one third of 
countries do not allow prison as a penalty in certain circumstances; of the remainder, many 
have lower-level guidance advising against prison for that offence.
All countries’ laws punish drivers adversely influenced by cannabis; some punish those found 
with traces in the body. The use of saliva test kits at the roadside is increasing, but in most 
countries a blood sample is required for actual prosecution.
Since 2000, the trend is to reduce the maximum penalty for use-related offences. The best 
available evidence does not show a clear or consistent effect of penalty changes on use rates.
Discussions of policy change include lowering penalties. There have been several proposals 
for full legalisation presented to parliaments in the last few years, usually by opposition 
parties, but most have already been rejected. No national government in Europe is in favour of 
legalisation.
6Part 1
What is cannabis and what are 
countries’ obligations to control it?
Part 1 sets out to clarify the definition of cannabis. In this 
time of increasing debate about the legal status of 
cannabis, this is crucial to understanding some of the 
provocative declarations that ‘cannabis is legal’ or ‘has 
been legalised’ in a particular country. This section 
examines what sort of cannabis is controlled, noting the 
different plant varieties, the parts of the plant, including 
the seeds, and the relevance of cannabis potency. It 
outlines how using parts of the cannabis plant for medical 
and industrial purposes is permitted under European or 
national legislation. The section then focuses on the use of 
cannabis for recreational purposes. It outlines how the EU 
countries are bound to control cannabis following their 
obligations under United Nations drug control treaties. It 
describes the extent of those controls and the 
corresponding room for manoeuvre open to countries 
which choose to vary their legislation within those 
international obligations.
|  What sort of cannabis is controlled?
The cannabis plant is usually legally controlled when it is 
capable of producing a useable amount of the 
psychoactive substance delta-9-tetrahydrocannabinol 
(THC), but some countries control all strains, even those 
where the THC content is negligible. The plant has been 
grown for several hundred years for fibre, oil, medicines 
and drugs. Since 1961, international law has defined the 
cannabis plant as ‘any plant of the genus Cannabis’, to 
cover the species Cannabis indica and Cannabis sativa 
and any variety discovered in the future (United Nations, 
1961). The roots and seeds have no THC, dried stem 
material will typically contain 0.3 % or less, and the lower 
leaves less than 1 %. However, in the female flowers, and 
the resin-producing trichomes (plant hairs) that grow 
among them, THC concentration can reach 20 % or more. 
In the European recreational cannabis market, the flowers 
may be sold still coated with the resin (‘herbal cannabis’), 
or the resin may be extracted and sold by itself (‘cannabis 
resin’). By 2015, the mean potency of samples analysed 
around Europe had risen by 90 % for resin and 80 % for 
herb compared with 2006 values. In 2015, the estimated 
national mean potency of cannabis resin samples in the 
EU Member States ranged from 4 % to 28 % THC, while 
that of herb samples ranged from 3 % to 22 %.
The international treaties require that the entire plant is 
controlled under national drug laws, although in European 
countries there may be exceptions for plants which have 
a THC content not exceeding 0.2 %, if grown for fibre. 
National control is not obligatory for cannabis seeds, 
although they are specified as subject to the drug control 
laws in Cyprus and Portugal. In other countries, supply of 
cannabis seeds for cultivation is often covered by a more 
general offence of ‘facilitating drug production’ or 
something similar.
Cannabis products: terminology
Cannabis products are used for medicinal and industrial 
purposes, as well as for intoxication. At least four US 
states and one EU Member State now have two 
separate distribution systems for intoxicating cannabis 
running in parallel, besides any industrial use of the 
non-psychoactive parts of the plant. Clarity is needed 
when discussing the laws involved.
Cannabis products that are used for medicinal 
purposes — whether the psychoactive THC or the 
non-psychoactive cannabidiol (CBD) — are generally 
referred to as ‘medical cannabis’. Cannabis products 
used in manufacturing are commonly referred to as 
‘industrial hemp’. Cannabis products used for non-
medical intoxication have been variously referred to as 
non-medical cannabis, retail cannabis and recreational 
cannabis. The term ‘non-medical’ cannabis does not 
make clear that it may not be for industrial purposes, 
while ‘retail’ refers to the form of distribution, rather than 
the motive for use such as ‘medical’ and ‘industrial’. 
Therefore, this report uses the term ‘recreational’ for the 
psychoactive cannabis products intended for non-
medical intoxication.
|  Is medical cannabis legal?
International law does not prevent cannabis, or cannabis-
based products, being used as a medicine to treat defined 
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indications. According to the UN conventions, the drugs 
under international control should be limited to ‘medical 
and scientific purposes’. Article 28 of the 1961 Convention 
describes a system of controls required if a country 
decides to permit the cultivation of cannabis that is not for 
industrial or horticultural purposes, while the 1971 
Convention controls THC.
In European countries, authorised medicines may include 
THC in capsules, cannabis extract as a mouth spray, and 
dried cannabis flowers for vaporising or making ‘tea’ (see 
Table 1).
By contrast, no country authorises the smoking of 
cannabis for medical purposes. There are two main 
reasons for this. First, there are many strains of cannabis 
plants, and each variety has the capacity to produce 
a range of chemicals. The range and concentration of 
chemicals may also vary within one plant, for example 
depending on light levels during growth or maturity at 
harvest. If these factors are not strictly controlled, it is very 
difficult for a prescriber and pharmacist to judge the 
content and thus the delivery of the particular chemicals 
needed for the patient. Second, inhaling smoke from 
burning plant material is not a healthy method of delivery 
of those chemicals to the bloodstream, as the patient will 
also inhale harmful tars and particles. When the required 
chemicals are not psychoactive, such as CBD, it is also 
very difficult for the user to measure the dose correctly.
A medicine based on cannabis extract has been approved 
by the European Medicines Agency, and at the time of 
writing four EU countries have specific legal processes 
governing the distribution and use of medical cannabis.
Cannabis extract is the main active substance in a medical 
product commercialised around Europe under the brand 
name ‘Sativex’, which contains equal quantities of THC 
and CBD. This medical product, which is sprayed under the 
tongue, has been approved by the European Medicines 
Agency only to treat symptoms of multiple sclerosis. It is 
currently authorised as a medicine in 18 European 
countries (1). In some of these countries, national health 
insurance systems will reimburse the cost under certain 
conditions, such as prior approval or prescription by 
specialists.
Since 2001, the Office of Medicinal Cannabis (OMC) has 
been the Netherlands government agency with a monopoly 
on supplying medical cannabis to pharmacies and general 
practitioners in accordance with the terms of the 1961 UN 
Convention. Producers are licenced by the Dutch 
government and must sell all produce to the OMC, which 
then distributes it to pharmacies. The OMC offers varieties 
of medical cannabis, with different levels of THC (ranging 
from less than 1 % to approximately 22 %) and CBD 
(ranging from less than 1 % to approximately 9 %). These 
products cater for different patient needs at a cost of 
about EUR 45 for 5 grams. These may be prescribed for 
relief of symptoms arising from multiple sclerosis, HIV/
AIDS, cancer, long-term neurogenic pain, and tics 
associated with Tourette’s syndrome. Smoking is not 
recommended by the manufacturer, and the preferred 
methods of use include inhalation from a vaporiser and 
infusion in tea. In theory any doctor may prescribe medical 
cannabis, but in practice only a limited number do so. As of 
March 2015, about 1 200 patients get their medical 
cannabis, with a prescription from their doctor, through the 
pharmacy. There is no reimbursement from the national 
healthcare system, but there may be some partial 
reimbursement by supplementary health insurance.
In the Czech Republic, the State Agency for Medical 
Cannabis was established as a special department of the 
State Institute of Drug Control. It set rules for 
e-prescription, pharmacies and so forth, but a special 
register only started operating in November 2014. Use of 
medical cannabis products is only possible in line with the 
Ministerial Notice of 2013, and the prescription should 
(1) Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, 
Ireland, Italy, Luxembourg, Netherlands, Norway, Poland, Portugal, Slovakia, 
Spain, Sweden, United Kingdom.
TABLE 1
Authorised cannabis-based medicines in Europe at a glance
Brand name Description Indications Form
Sativex 
(Nabiximols)
Extract of cannabis (oil): THC and CBD Multiple sclerosis Sublingual spray
Marinol 
(Dronabinol)
Synthetic delta-9-THC Cancer treatment, AIDS, 
multiple sclerosis
Gelatin capsule
Cesamet 
(Nabilone)
Synthetic cannabinoid similar to THC Cancer treatment Capsule
Bedrocan Dried flower tips (sometimes powdered); five 
different strains available
Various Plant material
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state the mode of use and THC level (up to 21 %). Initially 
patient limits were 30 grams per month, but these were 
raised to 180 grams per month in October 2015. Currently 
only 16 specially qualified doctors, such as oncologists 
and psychologists, are authorised to prescribe cannabis, 
and only 26 pharmacies can dispense it. Patients must be 
aged over 18 years. The first domestic harvest was 
distributed to pharmacies in March 2016, with the final 
price to the patient being about EUR 3.70/gram (the 
average price of illicit cannabis in the Czech Republic was 
about EUR 7.40/gram in 2014).
In Italy, the Ministry of Health is the coordinating body for 
medical cannabis. From November 2015, the ministry can 
issue permits for cultivation, production, possession and 
use, and herbal cannabis may be prescribed with a non-
repeatable prescription; the use of cannabis is only for 
symptomatic treatment supporting standard treatments, 
where results cannot be achieved with traditional 
treatments. Eligible conditions are primarily spasticity, 
chronic pain, nausea from chemotherapy or HIV 
treatments, loss of appetite from cancer or AIDS, 
glaucoma, and Gilles de la Tourette syndrome. Licensed 
farmers deliver the cannabis to the ministry, which then 
allocates it for production. The pharmacist buys the active 
substance from the ministry with vouchers, and prepares 
magistral (2) preparations accordingly. Doctors should 
prescribe the most appropriate genetic strain, dispensing 
amount and consumption method (vaporising or infusion 
in hot water only) for each patient.
In Croatia, new regulations entered into force in October 
2015 that amended the Ordinance on classifying, 
prescribing and dispensing medicines, to allow the use of 
cannabis for medical purposes. Following the 
recommendation of certain neurology, infectious diseases 
or cancer specialists, medicines containing THC, 
dronabinol or nabilone can be prescribed, on non-
repeatable prescription, by physicians working in general 
and family practice, health protection of preschool children 
and women’s healthcare. These medicines may be 
prescribed to relieve the symptoms of multiple sclerosis, 
cancer, epilepsy and AIDS. They may be in various forms 
such as teas, ointments and other extracts including 
galenical preparations; smoking or vaping herbal cannabis 
is not permitted. The prescription should state the amount 
of THC in a single dose, the number of individual doses, 
drug form, dosage and method of use; also if applicable, 
the type of herbal drugs and herbal preparation which will 
make the main composition. Medicines containing THC 
can be prescribed in the quantity necessary for treatment 
(2) Magistral preparation: any medicinal product prepared in a pharmacy in 
accordance with a medical prescription for an individual patient. 
up to 30 days. The total amount of prescribed THC in 
30 days of treatment must not be greater than 7.5 grams. 
As at January 2017, no domestic cannabis was being 
grown for this purpose, but medicines were being 
imported.
|  Is industrial cannabis legal?
In the European Union,   it is legal to cultivate and supply 
cannabis plants for hemp fibre if they have low levels of 
THC. The granting of payments under the Common 
Agricultural Policy is conditional upon the use of certified 
seeds of specified hemp varieties; only varieties with 
a THC content not exceeding 0.2 % may be used (EU 
Regulation 1307/2013). Payments are therefore granted 
only for areas sown with varieties of hemp offering certain 
guarantees with regard to their psychotropic content. 
There is a procedure for the determination of hemp 
varieties and the verification of their tetrahydrocannabinol 
content. Imports of hemp are also subject to certain 
conditions to ensure the above-mentioned THC limit is 
respected (EU Regulation 1308/2013). According to the 
European Court of Justice, case C-207/08 (Babanov), the 
cultivation of hemp fulfilling the strict conditions above by 
farmers respecting all the other conditions established by 
the EU legislation cannot be prohibited in any Member 
State, if this prohibition conflicts with provisions of EU law 
or undermines the aims and objectives of these provisions. 
New countries joining the European Union, in which it was 
illegal to grow any cannabis plant under the narcotic 
control law, have sometimes needed to change their law in 
order to permit this exception.
From this point on, unless stated otherwise, this report will 
only discuss laws applying to cannabis used for 
recreational purposes.
|  Why should countries control cannabis — and to what extent?
To understand today’s cannabis control laws, we need to 
look at the history of international drug law, which binds 
signatory countries. Cannabis was first placed under 
international control by the Second Opium Convention of 
1925 (League of Nations, 1925). In Article 1, cannabis was 
referred to as ‘Indian hemp’, which covered only the dried 
or fruiting tops of the pistillate (female) plant, because 
these were considered to be particularly rich in the 
‘pharmaceutically strong active resin’. The 1925 
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Convention banned the export of cannabis resin to 
countries that prohibited its use (Article 11(a)) and 
required domestic controls, such as penalties for 
unauthorised possession, of cannabis extract and tincture 
(Articles 4,7). The convention established that any 
breaches of national laws should be punished by 
‘adequate’ penalties (Article 28).
The international drug control system has evolved since 
then, and currently three United Nations conventions 
describe the basic framework for controlling the 
production, trade and possession of over 240 psychoactive 
substances (most of which have a recognised medical 
use). These treaties, which have been signed by all EU 
Member States, classify narcotic drugs and psychotropic 
substances according to their danger to health, risk of 
abuse and therapeutic value.
The 1961 Convention (United Nations, 1961) classifies 
narcotic drugs in four schedules. Its 1971 counterpart 
(United Nations, 1971) places psychotropic substances in 
another four schedules. Some substances are listed twice 
in the 1961 Convention. Cannabis and heroin (as well as 
15 other substances) for instance are placed by the 1961 
Convention in Schedule I, as substances whose properties 
give rise to dependence and which present a serious risk 
of abuse. They are also included in Schedule IV, among the 
most dangerous substances, by virtue of the risks of 
abuse, their particularly harmful characteristics and their 
extremely limited medical or therapeutic value. This 
‘twofold’ classification appears to have been intended by 
legislators to stress the threat to public health posed by 
these substances, but it also has the consequence of 
limiting their possible use for medical purposes. However, 
since its inclusion in the 1925 Convention, cannabis resin 
has never been reviewed by the committee of health 
experts appointed to determine which substances should 
be internationally controlled. For this reason its 
classification has always been controversial (Danenberg et 
al., 2013). Latest evidence can be found in the WHO’s 
updated publication on ‘The health and social effects of 
nonmedical cannabis use’ (WHO, 2015).
The United Nations conventions provide that the use of all 
drugs (under control) must be limited to medical and 
scientific purposes. The conventions specify that 
unauthorised actions, such as possession, acquisition, 
distribution or offering for sale and so on, must be 
punishable offences, and that serious offences should be 
punished by the deprivation of liberty. The 1961 and 1971 
Conventions largely set out terms and mechanisms for 
(international) trade, so it was debatable how much they 
required punishment of possession only for personal use. 
However, the UN Convention of 1988 (United Nations, 
1988) specifically requested countries ‘subject to 
constitutional principles and basic concepts’ of countries’ 
legal systems, to establish ‘as a criminal offence […] the 
possession, purchase or cultivation of drugs […] for 
personal consumption’. Given the first part of this 
requirement, the different national interpretations of ‘a 
criminal offence’, and the possibility to provide for 
alternatives to conviction or punishment, there has been 
a wide variety in responses across Europe.
The conventions do not specify that drug use itself should 
be a punishable offence, although each country can 
establish simple drug use as a specific offence if it 
chooses to do so. In addition, the conventions make no link 
between the type of drug and the penalties established in 
national law. The schedules affect the procedures for legal 
trade of drugs, but countries are not bound to use them or 
other distinctions to vary penalties for offences. The 1988 
Convention also requested countries to take appropriate 
measures to prevent illicit cannabis cultivation and to 
eradicate cannabis plants on their territory (Article 14).
|  Is there a harmonised EU law on cannabis?
There is no harmonised EU law on cannabis use. The 
criminal or administrative response to drug use offences is 
the responsibility of EU Member States, not of the 
European Union. According to Article 168 of the Treaty on 
the Functioning of the European Union (TFEU), ‘The Union 
shall complement the Member States’ action in reducing 
drugs-related health damage, including information and 
prevention.’
There is some EU law affecting cannabis trafficking 
offences. With regard to drug trafficking, the European 
Union does have legislative competence to ‘establish 
minimum rules concerning the definition of criminal 
offences and sanctions in the areas of particularly serious 
crime with a cross-border dimension’, which specifically 
includes illicit drug trafficking (Article 83, TFEU). Based on 
this, a 2004 EU Framework Decision (2004/757/JHA) laid 
down minimum provisions on the constituent elements of 
criminal acts and penalties in the field of illicit trafficking in 
drugs and precursors, to allow a common approach at EU 
level to the fight against trafficking. Possession for 
personal consumption was specifically excluded from this 
framework decision. Member States were obliged to take 
measures necessary to ensure that the offences were 
punishable by ‘effective, proportionate and dissuasive’ 
criminal penalties. Besides this general obligation, 
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minimum and maximum levels of sanctions were provided 
for (Article 4). Aggravating circumstances include offences 
involving ‘those drugs which cause the most harm to 
health’ (Article 4 (2)(b)), but the definition of these drugs 
was left to Member States. For this and other reasons, the 
framework decision had little effect on national legislation 
(European Commission, 2009).
The Council Resolution on cannabis of July 2004 (Council 
of the European Union, 2004) encouraged Member States 
to take measures against cultivation and trafficking of 
cannabis within the Union, and to consider taking 
measures against internet sites providing information on 
cultivation.
There is also European legislation on industrial and 
medical cannabis products as outlined on pages 6–8.
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Part 2
What do the laws and associated 
guidelines say?
Part 2 discusses the legislative texts of Member States. It 
includes parliamentary and government laws, ministerial 
decrees, directives to national prosecutors and guidance to 
national police forces. In some cases, national sentencing 
guidelines and constitutional court decisions also shape the 
legal framework on cannabis. It examines how countries 
may use different penalty levels to distinguish between 
different drugs, or not, usually aiming to send a message 
about relative harms of the substances (popularly known as 
‘soft’ and ‘hard’ drugs). It shows how the criminalisation of 
consumption rather than just possession can be significant, 
because it can lead to arrest following a positive drug test 
for cannabis. The section illustrates the complexity of trying 
to define ‘decriminalisation’ across the many different legal 
systems of the European countries. This part also looks at 
the quantitative limits used to define different offences in 
terms of weight of cannabis or number of plants, and the 
ways in which these limits can be interpreted, including the 
implications that some offences will not be punished. 
Finally, there is a description of the wide ranges of penalties 
for cannabis supply across Europe and an introduction to 
the ways in which countries’ laws address safety concerns 
arising from cannabis use by road users.
|  Is cannabis legally the same as other drugs?
European countries may be divided into two groups in 
terms of the penalties imposed for cannabis offences (see 
Figure 1). In the first group, cannabis is treated differently 
from other drugs under the law, typically because penalty 
levels are applied according to the amount of harm that 
use of the drug may cause. In the second group, penalties 
under the law are the same for all drugs including 
cannabis, but instructions to police or prosecutors, and 
judicial discretion in practice, distinguishes between 
substances on the basis of relative harm, resource 
prioritisation or for other reasons. These distinctions may 
apply to offences related to use, supply or both.
In the first group of countries, lists or classes of drugs 
established in, or directly linked to, laws are used to 
determine different legal degrees of severity of penalty in 
definition and prosecution of offences. Cannabis is often 
included among those drugs that do not incur the 
maximum legal response. For example, in Cyprus, Italy, 
the Netherlands, Portugal and the United Kingdom, legal 
penalties for offences relating to the use and supply of the 
class of drugs including cannabis are less severe than 
those for offences related to other substances. Strikingly, 
no other substance listed in Schedule IV of the 1961 
Convention (which lists substances particularly liable to 
abuse and to cause ill-effects) attracts lower penalties in 
this way. By contrast, in Bulgaria and Romania, cannabis is 
listed as a substance that carries a higher degree of risk 
than drugs in other categories, and the penalty for supply 
is more severe. For (minor) use-related offences involving 
cannabis, penalties are set lower than those for other 
drugs in Belgium, the Czech Republic, Ireland, 
Luxembourg and Malta. For drug supply offences in 
Denmark, Finland and Spain, the law prescribes a higher 
penalty for drugs referred to as more dangerous or 
harmful. Prosecution and sentencing directives, and 
Penalty does not
vary by drug 
Penalty varies by drug for:
Personal possession
Supply 
Personal possession
and supply
FIGURE 1
Penalties in law for drug offences in the European Union, 
Norway and Turkey
CANNABIS LEGISLATION IN EUROPE
12
reports of jurisprudence, suggest that this does not 
include cannabis. Other countries treat use or supply of all 
drugs equally under the law.
|  Will a positive drug test for cannabis lead to arrest?
A positive drug test might lead to arrest if drug use (not 
merely possession for personal use) is a punishable 
offence under national law. Such an offence is not required 
by the UN conventions, which are primarily aimed at 
limiting drug supply. The 1988 Convention extended this to 
possession of drugs for personal use, when there is still 
a risk that the drug could be passed to another person. 
This risk disappears once the drug has been consumed. 
Nevertheless, several countries specify consumption as an 
offence, whether as a signal of society’s disapproval of 
drug use or as a practical measure to give police certain 
powers to investigate a crime or apprehend a user (see 
Figure 2). Consumption of cannabis is a serious offence, 
punishable with a prison sentence in Cyprus, France, 
Finland, Greece, Hungary, Norway and Sweden. It is an 
offence punishable by a fine or other minor penalty in 
Estonia, Latvia, Lithuania and Portugal; also in Spain if the 
consumption is in a public place. In all these countries, 
a positive drug test could theoretically lead to police 
action, but the law is implemented in different ways in 
different countries. In Estonia and Sweden for example, 
the law is used to enforce public order in cases of public 
intoxication; in Sweden it is also used to give the police 
power to apprehend drug users and direct them to 
treatment. In other countries, a drug test in a public place, 
and subsequent arrest, is only likely if the person is driving 
a vehicle, which is more a road safety policy than a drug 
control policy (see ‘Is it illegal to drive with cannabis in the 
body?’, page 16, for more details). More specific situations, 
such as safety-critical situations (e.g. operating machinery) 
or specific locations (e.g. prisons or military premises), may 
be addressed by other laws in different countries.
|  Can you be imprisoned for possession of a small amount of cannabis?
The unauthorised possession of cannabis for personal use 
is subject to a range of sanctions in the laws of EU 
countries, but not all of these include prison sentences as 
an option. Overall, there has been a general trend across 
Europe to reduce the likelihood of imprisonment for this 
offence since around 2000.
Penalty
 None
 Without incarceration
 Incarceration possible
Penalty
 Without incarceration 
 Incarceration possible
FIGURE 2
Penalties in law for consumption of cannabis in the 
European Union, Norway and Turkey
FIGURE 3
Penalties in law: possibility of incarceration for 
possession of cannabis for personal use (minor offence)
NB: In Spain consumption is penalised when the offence is committed in 
a public place.
NB: In Spain possession is penalised when the offence is committed 
in a public place.
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In some countries, in the absence of aggravating 
circumstances, the law does not allow imprisonment in the 
case of possession of small quantities of cannabis for 
personal use only (see Figure 3). In Bulgaria, Croatia, the 
Czech Republic, Italy, Malta, Portugal, Slovenia and Spain, 
this approach is applied to all drugs, while in Belgium, 
Ireland and Luxembourg, it only applies to cannabis. The 
non-custodial punishment is usually a monetary fine. 
Definitions of what constitutes a ‘small amount’, 
‘aggravating circumstances’, ‘minor possession’ and so on 
vary considerably between countries. In Belgium, while 
a prison sentence is theoretically possible for minor 
cannabis possession, police are instructed to give the 
lowest prosecution priority to non-problematic cases and to 
record the case locally but not centrally. In Austria, police 
report minor drug possession (for personal use) directly to 
the health authority and not to the judicial authorities in 
order to enable a faster health response and to allow public 
prosecutors to concentrate on more serious offences. In 
Estonia, the law for use or personal possession of any drug 
includes the punishment of ‘administrative arrest’ (detention 
in police cells) for up to 30 days; similar provisions were 
recently removed from the Latvian and Lithuanian laws. 
Apart from these conditions, and for supply of any small 
amount, prison sentences are still possible.
In other European countries, a prison sentence is possible 
according to the law, but in several of these, police or 
prosecutors are directed to use non-custodial penalties or 
powers of dismissal for minor ‘personal use’ offences. 
These countries include Denmark, France, Germany, the 
Netherlands and the United Kingdom.
In Denmark, the first response to personal possession 
should be a fine. In Germany, following a decision of the 
Constitutional Court in 1994, prosecutors will close a case 
that is considered to be minor according to certain criteria. 
These vary between federal states but typically relate to 
amounts of cannabis less than 6 grams. The Dutch Opium 
Act Directive instructs police to give the lowest 
investigation priority to possession of less than 5 grams of 
cannabis, with seizure on discovery the only action taken. 
In the United Kingdom, police guidelines instruct officers to 
give a warning for a first offence and a fine for a second.
|  Where is personal cannabis possession decriminalised?
To answer this question, it is necessary to define 
decriminalisation. In common use, decriminalisation 
denotes a move away from prohibition enforced by 
criminal sanctions. Other terms used to describe 
reductions in sanctions are depenalisation and 
legalisation, but these three terms may be used discretely 
or interchangeably, leading to inconsistent descriptions of 
countries’ laws. While operative definitions are possible 
(see below), other factors further complicate the issue. 
First, there is no agreed objective test for 
decriminalisation. This means that two experts could 
disagree on a classification of a country depending on the 
criteria they used (e.g. the status of the law that describes 
the offence, the severity of punishment prescribed, or 
whether an entry is subsequently made on the offender’s 
criminal record that is visible to employers). Second, 
although the popular terms used above may be applied in 
respect of the country’s laws, the implementation of those 
laws may differ in practice because of directives to police 
or prosecutors. Third, when considered literally, the terms 
‘decriminalisation’, ‘depenalisation’ and ‘legalisation’ 
describe a movement from one legal status to another. 
This makes the terms inaccurate when applied to countries 
where the law never established that an offence was 
criminal.
In simple terms the following distinctions should be noted:
■■ Decriminalisation refers to the removal of criminal 
status from a certain behaviour or action. This does not 
mean that the behaviour is legal, as drugs can be 
confiscated and non-criminal penalties may still be 
applied. In the drug debate, this term is usually used to 
describe laws related to personal possession or use 
rather than drug supply. Examples of countries which 
have decriminalised drug use or personal possession 
might include Luxembourg (only cannabis), Croatia, 
Portugal and Slovenia.
■■ Depenalisation refers to the introduction of the 
possibility or policy of closing a criminal case without 
imposing punishment, for example because the case is 
considered ‘minor’ or prosecution of it is ‘not in the 
public interest’. Examples may include Austria, 
Germany and Poland.
■■ Legalisation refers to making an act lawful that was 
previously prohibited. In the context of the drug debate, 
this usually refers to removing all criminal and non-
criminal sanctions, although regulations may limit the 
extent of the permission, as is the case for alcohol and 
tobacco. Penalties for breaching these regulations may 
be criminal or non-criminal. This term is generally used 
in the context of drug supply. Examples might include 
the systems in Uruguay and the US states of Alaska, 
Colorado, Oregon and Washington; in Europe, the 
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Dutch system of cannabis sale through coffeeshops is 
only the toleration of an unlawful act (see page 15).
The EMCDDA has published a short animation to explain 
the differences (EMCDDA, 2015b).
|  What’s the limit to personal use?
Some EU countries establish quantity limits for personal 
possession, which means that a person found with more 
than this amount of a drug may be prosecuted for a more 
serious offence such as supply (e.g. Estonia, Lithuania, 
Netherlands, Slovakia). Other countries also establish 
quantity limits in their drug laws, but for other purposes. 
For example, a country may define the minimum 
quantity — often together with other criteria — for criminal 
prosecution for a personal possession offence; possession 
of an amount below that limit may lead to a non-criminal 
penalty (e.g. Belgium, Czech Republic) or the case may be 
suspended, diverted or closed (e.g. Austria, Germany). 
Quantity limits may be established at different legal levels 
(laws, guidelines), and they may be established for many 
drugs or for just a few. Weights may be specified as total 
weight of the seizure, or weight of THC within the herb or 
resin. In some cases, quantities are defined in terms of the 
number of ‘doses’, or by monetary value. In most countries, 
threshold quantities are understood as guidelines, with 
exceptions allowed if justified.
There is little consistency between countries in the limits 
they set. The quantities for similar offences differ between 
countries. For example, criminal prosecution for 
possession of cannabis resin will start with 0.25 grams in 
Lithuania but only at 6 grams in many German federal 
states. The relations between the threshold quantities for 
the different drugs also vary widely across countries. 
For a given offence, the established weight threshold of 
cannabis herb may be equal to that of resin (Belgium), or 
twenty times more (Lithuania). The weight threshold for 
cannabis may be three times (Cyprus) or ten times 
(Netherlands) that of heroin.
In some countries where the law specifies ‘small’ or ‘large’ 
quantities, no limits have been set out in legislation or in 
police or prosecutor guidelines. Instead, these terms are 
interpreted by expert opinion or judicial precedent. This is 
the case in countries such as Croatia, Greece, Poland and 
Slovenia.
Limits, like penalties, change, as countries seek to improve 
the functioning of their legislation. In 2004, Bulgaria 
removed its exemption for punishment for possession of 
only ‘one dose’ of drugs. In 2005, Italy introduced quantity 
limits for personal possession (500 mg of THC) in a law 
which was annulled (for unrelated reasons) in 2014. The 
United Kingdom introduced a presumptive quantity of 
supply in the law in 2005, but the clause was not enforced 
after a consultation found there were no amounts which 
were universally appropriate. In Austria, a criminal 
prosecution could be suspended for possession of a ‘small 
quantity’ until 2007, when the reference was removed 
because it was considered imprecise. In 2013, Greece 
removed its defined quantity limit for personal use that 
had been introduced just a few years earlier. Instead it 
allowed the judge to decide if an amount discovered was 
intended for ‘personal use’, based on a range of factors 
that included purity, quantity and the characteristics of the 
particular user.
|  Do countries take a different approach to growing cannabis for personal use?
A few countries define the exact quantity of cannabis plants 
that will lead to prosecution or punishment, while others 
take a more general approach. In Belgium, cultivation of not 
more than one plant should be a minor offence resulting in 
a fine, and in the Netherlands, cultivation of not more than 
five plants would normally not be formally prosecuted. In 
Cyprus, cultivation of three or more plants is presumed to 
be a supply offence. In Denmark, prosecution guidelines 
consider 100 grams of cannabis plants as the limit for 
possession for personal use. In the United Kingdom, the 
2012 drug offences sentencing guideline proposes the 
starting point as a fine or community order for cultivation of 
nine plants. In Portugal, where drug use and personal 
possession offences were decriminalised in 2001, 
cultivation of any amount, even for personal use, remains 
a criminal offence. Similarly, the decriminalisation of 
personal possession offences in Croatia, from 2013, 
specifically excluded cultivation, meaning that owning one 
plant for personal use could be punished by a sentence of 
6 months to 5 years imprisonment. In Finland, any 
cultivation is considered as a narcotics offence, which is 
more serious than an offence of unlawful narcotics use. By 
contrast, in Spain, since 2015 cultivation for personal use in 
places visible to the public is considered an administrative 
offence, only punishable by a fine.
In some countries, the lower priority given to prosecuting 
owners of one plant has been interpreted by some plant 
owners as permitting collective growing, known as 
cannabis social clubs (see page 15), although these clubs 
are not legally recognised by national governments.
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|  Is it true that growing or buying cannabis is legal in some places?
In considering this question, readers are advised to bear in 
mind three points: (1) the key differences between 
legalisation, decriminalisation and depenalisation; (2) any 
limits to prosecution or penalties for personal cultivation, 
described above; and (3) that medical use of cannabis or 
cannabis extract may be legal, as described in Part 1.
|  Coffeeshops in the Netherlands
In the Netherlands, cultivation, supply and personal 
possession of cannabis are all criminal offences, 
punishable with prison sentences according to the law. 
However, a practice of tolerance, first set out in local 
guidelines in 1979, has evolved into the present-day 
concept of ‘coffeeshops’, that is, cannabis sales outlets 
licensed by the municipality. About two thirds of 
municipalities do not allow coffeeshops, and the number of 
coffeeshops across the country has decreased, from 846 
in 1999 to 614 in 2013. The sale of small quantities of 
cannabis to adults (aged over 18) in coffeeshops is 
tolerated in an attempt to keep young adults who 
experiment with cannabis away from more dangerous 
drugs (a policy referred to as ‘separation of the markets’).
A coffeeshop may be closed down and the operator or 
owner prosecuted if he or she does not meet the 
Prosecutor General’s criteria, which prohibit advertising, 
nuisance, sale to minors and sale of hard drugs or alcohol. 
A scheme to convert coffeeshops into closed clubs with 
registered members was trialled and then dropped in 
2012. From January 2013, coffeeshops can only legally be 
used by residents of the Netherlands on production of an 
identity card or residence permit. Nevertheless, 
implementation and enforcement of this rule varies by 
municipality.
A proposal to limit coffeeshop sales to cannabis products 
with THC levels under 15 % remains pending while 
enforcement issues are addressed. No more than 5 grams 
may be sold to any person in any one transaction and the 
coffeeshop is not allowed to keep more than 500 grams of 
cannabis in stock. Yet wholesale cultivation and 
distribution of cannabis is not tolerated in the Netherlands, 
resulting in what is known as ‘the back-door problem’, that 
is, drugs may be ‘legally’ sold at the front door of the shop 
but cannot be legally supplied to the back door. Although 
there have been many proposals to resolve this 
inconsistency, to date no solution has been agreed. 
Alongside the coffeeshop system, police have the 
discretionary power to confiscate small amounts of 
cannabis or plants cultivated for personal use, but the 
owner will not be formally prosecuted if he or she hands 
them over voluntarily.
An evaluation of the Dutch drug policy in 2009 found that 
the coffeeshops were the main source of cannabis for 
users, the markets for soft and hard drugs remained 
separate, and adult cannabis use was relatively low 
compared with other European countries (WODC, 2009). 
However, underage use was high (whether due to 
coffeeshops, greater acceptance of use, or other factors), 
there was serious nuisance from drug tourism, and the 
sector had become increasingly commercialised and of 
interest to organised crime. The most recent legal 
developments described above took place partly in 
response to this evaluation.
|  Cannabis social clubs
Cannabis social clubs operate on the assumption that if 
one person will not be prosecuted for cultivating one 
cannabis plant in private for his or her own use, then 20 
people should not be prosecuted for cultivating 20 plants 
together in private for their own use. Clearly this concept 
is not without problems. Establishing what constitutes 
‘shared’ production, for example, is problematic, and it is 
unclear how these activities can be legally distinguished 
from supply offences. Across the European Union, drug 
supply offences themselves have varying legal definitions, 
but usually require the passing of drugs between persons 
and some quantity criteria may also apply.
In response, cannabis social clubs have tried to establish 
operating rules in order to avoid charges of trafficking, 
drug supply or encouraging drug use. For example, the 
advocacy group Encod has proposed that clubs should 
operate as a collective agreement, with a register of 
members, costs calculated to reflect expected individual 
consumption, and the amount produced per person 
limited and intended for immediate consumption 
(ENCOD, 2011). Clubs should be closed to the public, and 
new members should be existing cannabis users who are 
accepted only by invitation. This model, although 
promoted by activists in Belgium, France, Germany, 
Slovenia and Spain, is not tolerated by national 
authorities in any European country. This means that 
clubs cultivating cannabis are likely to be subject to legal 
sanctions should they be identified or, at least, are 
operating in a legal grey area.
It is difficult to know to what extent these social clubs exist 
in Europe, although they do appear to be rare. The city of 
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Utrecht in the Netherlands announced a project to develop 
such a club in 2011, but the project has not yet been 
implemented. Some clubs report that they are operating 
on a limited basis in some Spanish regions, taking 
advantage of the fact that, although production, supply 
and personal possession of cannabis in public are 
prohibited under Spanish law, possession in private 
spaces is not penalised. The legal position on shared 
consumption is more complicated, but in 2015 three 
judgements of the Supreme Court in Spain concluded that 
organised, institutionalised and persistent cultivation and 
distribution of cannabis among an association open to new 
members is considered to be drug trafficking.
|  What are the possible penalties for cannabis sale or trafficking?
The maximum penalties for cannabis supply offences vary 
considerably between European countries in ways that can 
be difficult to describe simply. For example, the maximum 
penalties for minor cannabis supply offences range from 2 
to 3 years in Denmark, Estonia, Finland, Norway, Spain and 
Sweden to life imprisonment in Cyprus, Ireland and Malta. 
However, the first group of countries have established 
a scale of offences with graduated punishments, within 
which an offence of aggravated supply may attract 
maximum sentences of 15 to 20 years in prison, while the 
second group of countries have one maximum sentence 
for any supply offence, but allow judicial discretion to play 
a wider role.
The penalty range allowed in countries’ laws may depend 
on a variety of defined aggravating circumstances, not just 
the substance involved. This makes direct comparison 
between countries much more difficult. Analysis of 
legislation reveals that factors affecting the penalty 
imposed will often include the amount of drug involved, 
whether organised crime or gangs are involved, the motive 
(profit-seeking or other supply) and sometimes even the 
court in which the offender is tried (e.g. Ireland, Malta, 
United Kingdom). Analysis of prosecutor directives and 
sentencing guidelines reveals further nuances.
One way of comparing penalties set out in the laws is to 
combine offence sentence ranges with the quantity 
threshold data that are available from a few countries. 
Supplying amounts up to a few hundred grams of cannabis 
resin is punishable by prison sentences of several years in 
Hungary, Lithuania and Slovakia. In Hungary, for example, 
supply of more than 6 grams of THC (e.g. 60 grams of resin 
with a potency of 10 %) increases the range of the possible 
sentence from up to 2 years to between 2 and 8 years. 
However, penalties are increased in Austria, Denmark, 
Finland and Spain when amounts of the order of kilograms 
are involved. In Denmark, the Director of Public 
Prosecutions’ notice, revised in 2008, states that the guide 
quantity is about 10 kilograms of resin or 15 kilograms of 
herb to bring a prosecution under the criminal code (with 
a penalty of up to 10 years in prison), rather than under the 
Act on Euphoriant Substances (with a penalty up to 
2 years in prison).
At the other end of the scale is the concept of minor 
supply. Although some laws consider the (lack of) profit 
motive of the offender, there have been attempts to take 
account of group use, where the practice of sharing 
a cannabis cigarette amounts to an offence of supply, 
which may require a proportional response. Belgium 
removed ‘drug use in a group’ as a criminal offence in 
2003. Malta, acknowledging that a minimum penalty of 
6 months for supply was disproportionate in such cases, 
changed the law in 2006 to permit exclusion of that 
punishment for a first offence, if ‘the offender intended to 
consume the drug on the spot with others’. In Hungary, 
a clause introduced to the drug control sections of the 
penal code in 2003 allowed suppliers to qualify for 
diversion to a treatment alternative to punishment, if the 
offence ‘involves a small quantity offered or supplied to be 
consumed jointly’. The following year, however, the 
Constitutional Court struck down the clause, on the 
grounds that the word ‘jointly’ was too vague to form the 
basis of a criminal offence.
|  Is it illegal to drive with cannabis in the body?
A review of the available evidence has found that driving 
after cannabis intoxication and recent use of cannabis 
increased the risk of a car accident by 35 %, and the 
presence of a high level of THC in the blood may double 
the risk (a 100 % increase) (Rogeberg and Elvik, 2016). In 
all countries in Europe, it is illegal to drive when skills are 
reduced due to cannabis consumption, but the laws vary, 
both in their phrasing and in their interpretation. In some 
countries, it is illegal to drive ‘under the influence’, that is, 
while driving skills are adversely affected. In these 
countries, if the driver is able to pass cognitive or 
psychomotor tests, such as walking in a straight line, no 
driving offence has been committed, even if biological 
samples taken from the driver test positive for the 
presence of cannabis metabolites. In other countries, it is 
illegal to drive ‘after the consumption’ of drugs, with no 
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reference to effects on driving skills. In these countries, 
a positive urine test for cannabis metabolites, which could 
reflect cannabis consumption several days earlier, may 
lead to a drug-driving conviction in the absence of any 
visible effect on driving skills at the time of the test. These 
two examples suggest different policy emphases: on traffic 
safety and on illicit drug control, respectively. Yet the 
distinction is not always clear because, in practice, some 
experts report that ‘under the influence’ may be 
interpreted by prosecutors as including any trace of drugs 
in a biological sample.
Over the last 10 years, the matter has become more 
nuanced. Aided by advances in roadside screening 
technology, some countries have introduced laws that 
penalise drivers found with the presence of more than 
a defined amount of THC in their blood. The specified level 
may vary, from a low level that confirms the presence of 
the drug (Denmark, Spain, United Kingdom), to a level that 
is considered equivalent to the drink-driving limit (Norway). 
Roadside oral fluid screening devices are now being used 
in 15 countries (3).
As policymakers try to avoid condoning drivers with small 
amounts of illicit substances in their bodies, the binary 
classification of drugged driving as ‘legal/illegal’ is being 
replaced in several countries by graduated punishments, 
with a lower punishment for any detection of THC and 
a higher one for being clearly impaired (such as in Belgium, 
Germany, Finland, Spain, United Kingdom). There is also 
the possible combination of road safety and drug laws: 
when cannabis metabolites are detected in a driver at 
levels unlikely to impair driving, the driver can be charged 
with a drug use offence, rather than a road traffic offence 
(as reported in Finland and Norway).
(3) Croatia, Cyprus, Czech Republic, Denmark, Finland, France, Italy, 
Luxembourg, Norway, Poland, Portugal, Romania, Slovenia, Spain, United 
Kingdom. 
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Part 3
What happens to cannabis offenders 
in practice?
Analysing a country’s legislation does not in itself reveal 
how laws are enforced. The laws will primarily be 
implemented by the police forces, which may have powers 
of discretion or be subject to local or national directives 
that prioritise their responses to different offences. Hence, 
if cannabis use or personal possession is a crime, it does 
not follow that every cannabis user found will be convicted. 
The rise in cannabis use in different countries in Europe has 
seen discussion of whether police should give cannabis 
use a lower priority in times of reduced resources, or an 
increased priority due to concomitant rise in harms. Police 
priorities may also be affected if recorded actions are used 
as a performance measurement of law enforcement 
effectiveness. Increases in the numbers of cannabis users 
in treatment may or may not be due to the increased use of 
treatment as an alternative to punishment. This section 
describes how the laws are implemented: how cannabis 
offenders enter the criminal justice system, usually on 
discovery by police or other law enforcement, and 
eventually how they leave it and how such cases are closed; 
whether by a police warning, diversion to treatment or 
counselling, or appearing in front of the prosecutor or the 
court with the possibility of different outcomes, most often 
a fine or, occasionally, a prison sentence.
|  How much do the police focus on cannabis users?
There are conflicting views on how much the police focus 
on cannabis users. One view suggests that the 
performance management approach of setting annual 
targets, which has spread across Europe during the last 
two decades, may have unintentionally encouraged law 
enforcement agencies to focus on cannabis use cases 
because they are simple to pursue, numerous and easy to 
‘solve’. Another view is that, particularly in times of 
stretched resources, the police may overlook ‘minor’ 
offences in order to concentrate on the more serious ones, 
and in some countries minor offences can include use or 
personal possession of cannabis. While these approaches 
may vary even from city to city and from month to month, 
we can discern a broad trend across Europe by examining 
police and other law enforcement actions through the 
number of drug law offences reported annually.
The EMCDDA collects routine data on drug law offences 
from EU Member States, Norway and Turkey. Broadly 
speaking, these are law enforcement reports of acts that 
breach drug laws, usually recorded regardless of any 
subsequent charge or penalty (EMCDDA, 2015a). It is 
estimated that around 1.5 million drug law offences are 
reported each year in the European Union. Of these, about 
760 000 were related to cannabis in 2015, 609 000 of 
which were cannabis use-related offences (usually use or 
personal possession). Because some countries do not 
report recorded warnings or minor offences to the 
EMCDDA, these numbers almost certainly underestimate 
the true extent of drug law offences in Europe. An EU index 
of cannabis use-related offences, based on data provided 
by 18 Member States, shows this number has increased by 
27 % between 2006 and 2015. Looking at individual 
countries, increases in cannabis use-related offences do 
not seem to be related to changes in the estimated rates of 
cannabis use. This may be because the number of drug law 
offence reports for cannabis use depends more on police 
activity than on the number of cannabis users in a country.
The increase in offences related to cannabis use suggests 
that, in general, police in Europe stop and record cannabis 
users, rather than overlook them — though there may still 
be other explanations for this increase, such as greater 
police attention towards drug users, or more open use. 
Nevertheless, because recording a cannabis user is only 
the first step in the justice system, we also need to ask 
how users eventually leave that system, usually with 
punishment or some form of treatment.
|  What is the most common punishment for cannabis use?
An EMCDDA study indicated that many countries give fines, 
warnings or community work orders for offences of use or 
possession of drugs for personal use, although some 
central and eastern European countries, such as Bulgaria, 
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Poland, Romania and Slovakia, were more likely to use 
suspended prison sentences (EMCDDA, 2009). 
Unfortunately, the drug involved was rarely identified in the 
data used in the study, and this continues to be the case in 
sentencing or other outcome data reported to the EMCDDA.
In the United Kingdom (England and Wales), there is 
a specific legal disposal for the possession or use of small 
amounts of cannabis (and, since 2014, khat) — police may 
give a verbal ‘cannabis warning’ which results in no further 
legal action. About 46 700 cannabis and khat warnings 
were given by police in the year ending March 2015, nearly 
double the number of all punishments issued in court for 
possession of class B/C drugs.
In other countries which collect data on outcomes of use 
or personal possession offences for drugs, bearing in mind 
the high proportions of drug law offences that involve 
cannabis, it can be reasonably assumed that the majority 
of outcomes recorded were for cannabis possession.
In Austria, a temporary suspension of prosecution is 
possible for minor drug offenders, and this is the outcome 
in over 12 000 cases recorded in 2015, as opposed to 
some 3 000 convictions for misdemeanour offences. In the 
Czech Republic, 2015 saw nearly 2 000 administrative 
proceedings (punishable by a fine) for possession of small 
amounts of drugs, compared with less than 400 criminal 
sentences for personal possession of amounts greater 
than small. In Portugal, anyone found by the police who is 
using or possessing a small amount of drugs is sent to 
a commission for dissuasion of drug addiction, which is 
tasked with identifying the reason for drug-taking and 
deciding on the most appropriate sanction to stop it. An 
occasional drug user coming before a commission for the 
second time is likely to be told to report periodically to 
a chosen location, or receive a fine of EUR 30–40, and 
proportionally more on further occasions.
|  Where and when are cannabis users treated rather than punished?
The majority of countries in Europe appear to opt for 
policies of decriminalisation or depenalisation of offences 
related to cannabis use, either by using non-criminal 
punishments or simply closing the case as minor. However, 
some countries have options for alternatives to 
punishment, diverting the users to a rehabilitative 
measure. In those countries, even users without any 
diagnosis of addiction, who commit minor drugs 
possession offences, may be eligible for diversion to 
a counselling or rehabilitation course (Croatia, France, Italy, 
Luxembourg, Latvia, Malta, Portugal).
Drug users in Italy are interviewed by the Prefecture and 
then may be sent to a local public drug addiction services 
unit to complete a rehabilitation programme. In 
Luxembourg, the prosecutor may suspend proceedings; in 
Latvia, the court may suspend a punitive sentence, on 
condition that the offender attends some form of 
treatment or counselling course. In Croatia, the court may 
sentence an offender to undergo rehabilitative measures. 
In Malta, the Drug Dependence (Treatment not 
Imprisonment) Act 2015 introduced a new system in which 
a second drug offence would lead to an assessment by 
a three-person panel that could make a treatment order.
In France, a ‘drugs awareness course’ was established in 
2007 as an option to ensure that the criminal justice system 
and the prosecutor can make a constructive and 
proportionate response to occasional, non-problematic 
cannabis users rather than simply dismiss minor cases or 
give a criminal conviction. The offender has to pay the cost 
of the course, which currently averages EUR 160–230, but 
cannot be more than EUR 450. This may be interpreted as 
a response with both rehabilitative and punitive effects. 
However, this measure has not been widely implemented. 
An evaluation carried out by the French drugs observatory 
(OFDT) in 2012 found that the use of the courses had been 
rather modest; about 4 500 courses were awarded annually, 
while over 120 000 people had been stopped for cannabis 
offences in 2010 (Obradovic, 2012). This increased to 
11 801 courses in 2013. There was little consistent 
application nationwide, both in terms of the number of 
courses awarded and the costs charged to the users.
In Portugal, in 2015, rulings of the dissuasion commissions 
regarding all drugs were to suspend the process in 5 953 
cases, to issue punitive rulings in 1 608 cases, and to 
suspend the process with treatment in 809 cases. In 
recent years, around 60–65 % of suspensions were for 
users who were not considered to be addicted and 
15–20 % were suspended when the user agreed to 
undergo treatment.
More information on where and when drug law offenders 
are sent to treatment is available from drug treatment 
demand data. Each year, European countries provide the 
EMCDDA with anonymised data on those entering 
specialised drug treatment. Overall in Europe, the number 
of cannabis users entering drug treatment for the first time 
in their life (‘new treatment clients’) has more than doubled 
between 2003 and 2014 (4). Each year since 2009, among 
(4) From 31 178 in 2003 to 67 444 across 23 European countries.
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new treatment clients in Europe, cannabis has been the 
drug most often reported as the main reason for seeking 
help. There is no standardised scale that might indicate 
severity of cannabis use and related treatment need, but 
high frequency of use may be considered as a proxy. From 
data referring to 2014, more than one third (37 %) of new 
cannabis treatment clients reported that they used 
cannabis daily in the month before they entered treatment.
The practice of referring cannabis users from the criminal 
justice system to drug treatment differs markedly across 
Europe. In 2014, among countries with more than 100 new 
cannabis treatment clients, 5 % of such clients in the 
Netherlands were referred by courts, probation and police, 
while in Hungary the proportion was 84 %. As data are 
aggregated at European level, it is not possible to ascertain 
use frequency for this subgroup of referrals from criminal 
justice, but it is possible to compare the two datasets of 
frequency of use and source of referral for new cannabis 
treatment clients. This comparison shows diverse 
relationships between the two groups. In some of those 
countries, such as Finland, France, Italy and Portugal, the 
proportion of these clients who are daily users is similar to 
the proportion referred by the criminal justice system. 
However, in Ireland, the Netherlands and Turkey, a large 
proportion of new cannabis treatment clients are daily 
users, while the percentage of first-time cannabis clients 
referred by the criminal justice system is small. Conversely, 
in Croatia, Germany and Hungary, a relatively small 
proportion of new cannabis treatment clients are daily 
users, yet a much larger proportion has been referred by 
the criminal justice system. Therefore, across Europe, no 
consistent relationship can be discerned between the 
frequency of cannabis use among treatment entrants and 
the likelihood of referral into treatment by the criminal 
justice system.
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Part 4
Where is cannabis legislation going?
Over the last 20 years, the trend in laws has been to reduce, 
even remove, prison penalties for minor cannabis possession 
offences, although in some countries penalties have 
increased. These penalty changes may apply specifically to 
cannabis offences or to minor offences involving any drug. 
The EMCDDA has analysed the available data on prevalence 
of use before and after each change, in order to draw 
possible lessons for policymakers. Researchers have also 
examined the effects of policy changes in France, the 
Netherlands and the United Kingdom on use.
All changes to date in Europe have been to adjust the size of 
the penalty; no country has removed all penalties or 
permitted the legal distribution of cannabis. Nevertheless, 
there are a number of minor indicators of interest in 
changing cannabis legislation — whether to decriminalise, or 
to legalise, recreational use of cannabis in various countries 
around Europe. Several examples are described here. (There 
are also discussions regarding medicinal and industrial use 
of cannabis but they are not analysed here.)
|  How and why have countries changed laws (or punishments) for possession of 
cannabis?
Since the EMCDDA began monitoring drug laws in the late 
1990s, the general trend among countries has been to 
reduce the legal penalties for cannabis use-related 
offences, as summarised in Table 2. This statement, 
however, refers to the legislation and police or prosecutor 
directives only. In the absence of comparable national data 
on criminal justice system outcomes, it is not possible to 
comment on how these punishments are put into practice.
Changes have been made to laws on cannabis possession, 
or the penalties attached to them, for various reasons. 
These include ensuring that punishments are consistent, 
matching the severity of punishment to the health risks of 
different drugs and prioritising treatment over punishment.
In 2003, a Policy Note in Belgium set out a policy of 
standardising the punishment of cannabis users by 
introducing a minor fine. This was done because, 
previously, punishments were not applied uniformly as 
a result of vagueness in the law.
In 2004, the United Kingdom reclassified cannabis from 
class B to the lower class C. This change aimed to deliver 
a more effective message about the graded dangers of 
different drugs and to allow law enforcement to focus on 
‘class A’ drugs that cause the most harm. However, in 
2009, cannabis was again classified in class B as 
a precautionary measure in response to both the known 
and uncertain long-term health impacts of higher potency 
cannabis.
In 2006, Italy removed the legal distinction between two 
classes of illicit drugs, effectively raising the penalty for 
possession of cannabis for personal use. This was done to 
reaffirm that substance abuse is illegal and that all 
substances, regardless of their effects, are dangerous and 
TABLE 2
Types of change in law for cannabis use-related offences
Form of change Countries, year(s) of change
Reducing the maximum prison sentence Finland (2001), United Kingdom (2004), Greece (2006, 2013), 
Czech Republic (2010)
Removing the prison sentences for minor offences (may include 
changing the status of the offence from criminal to non-criminal)
Portugal (2001), Luxembourg (2001), Belgium (2003), Slovenia 
(2005), Croatia (2013), Malta (2015)
Decreasing the non-prison penalty Italy (2014)
Increasing the non-prison penalty Denmark (2004), Italy (2006)
Increasing the prison penalty United Kingdom (2009), Hungary (2013)
Facilitating closure of a minor case Austria (2008, 2015), Poland (2011)
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damaging. In February 2014, the Constitutional Court 
declared that amendment illegitimate (for unrelated 
reasons), and therefore a new amendment was passed. 
Penalties for minor personal use offences, such as 
suspension of the driving licence, are now 1–3 months for 
cannabis and other less dangerous drugs and 
2–12 months for the more dangerous drugs. Penalties for 
larger-scale offences now include a lower sanction range 
(penalties reduced by between one third and one half) for 
substances with a lower health impact, such as cannabis.
In France, a new ‘drugs awareness course’ was introduced 
in 2007, which aimed to provide a measure by which the 
judiciary could send cannabis users to educational 
courses rather than the more intense treatment courses — 
or dismissal of the case — that had been the only non-
punitive response before.
In other countries, changes in laws on cannabis were 
incidental to changes in laws targeting other drugs. This 
included the decriminalisation of all illicit drugs in Portugal 
in 2000, in response to the country’s heroin problem; 
a 2005 change in Slovenia, which removed prison 
penalties for all types of minor offences (including drugs 
possession); a 2013 change in Croatia, which was 
motivated by considerations of proportionality in 
punishments; and a 2015 legal change in Malta, which 
aimed to rehabilitate persons suffering from drug 
dependence.
|  Do changes in laws affect levels of cannabis use?
It is not easy to show whether or not changes in the laws 
had effects on levels of cannabis use; though it should also 
be remembered that the primary objectives of the changes 
were to address other issues, as mentioned above. 
However, impact evaluations are rarely carried out because 
of the difficulty of assessing what would have happened 
without the law changes. Incomplete knowledge of how 
the laws are put into practice may create a further 
complication.
A concern is often expressed that, while penalties for 
cannabis possession (and their consequences) may seem 
relatively severe, reducing penalties for cannabis use will 
send a signal to young people that cannabis use is 
somehow more acceptable and thereby increase rates of 
use. Conversely, when cannabis use increases, concerns 
are expressed that the penalties are too low and should be 
raised in order to discourage use. To examine the evidence 
behind these assumptions, the EMCDDA published 
a simple comparison of cannabis use rates in the years 
before and after legal changes in countries where the law 
had changed (EMCDDA, 2011a). As cannabis use is 
concentrated among the younger age groups, the analysis 
was performed using EMCDDA prevalence data for 15- to 
34-year-olds, who had been asked if they had used 
cannabis in the last year.
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The legal impact hypothesis, in its simplest form, predicts 
that increased penalties will decrease drug use and 
reduced penalties will increase drug use. However, in the 
original analysis, and an updated version (Figure 4), no 
simple association can be found between legal changes 
and the prevalence of cannabis use.
In France, a study evaluated the effects of the introduction, 
in 2007, of drugs awareness courses that were aimed at 
occasional cannabis users (Obradovic, 2012). The 
evaluation, which surveyed 4 000 participants, found that 
the courses had a limited impact on their use of cannabis, 
partly because the courses were ‘not sufficiently 
personalised’. One fifth of users stated they would not 
change their behaviour (except to avoid being caught 
again). Although two thirds said they would stop or reduce 
their cannabis use, most of these had already started to 
reconsider their drug use immediately after their arrest, 
before they attended the course. The courses were also 
ordered infrequently, with only about 4 500 per year, 
compared with over 100 000 incidents of police 
questioning cannabis users.
In the United Kingdom, a study analysed the police and 
criminal justice statistics before and after the 
reclassification of cannabis in 2004 and 2009 and the 
introduction of a new, informal ‘cannabis warning’ (Shiner, 
2015). The use of formal police cautions for cannabis 
possession fell from nearly 40 000 to just over 20 000 per 
year, but the number of cannabis warnings rose to peak at 
about 100 000 in 2008. Police cautions for possession of 
other drugs also rose. Court convictions for possession 
dropped sharply in 2004–2006, but rose again to pre-
2004 levels by 2010. Meanwhile cannabis use rates for 
young adults fell steadily from their peak in 2002. These 
results illustrate the complexity of relationships between 
the penalty levels in the law, the punishments actually 
given, and the use rates.
One legal change which does seem to have had an impact 
was the decision to restrict students’ access to 
coffeeshops in the Dutch city of Maastricht, based on 
nationality: Dutch, German and Belgian citizens were 
permitted access, but others (including French and 
Luxembourgish) were not. Analysis of administrative panel 
data on over 54 000 course grades of local students 
enrolled at Maastricht University before and during the 
partial cannabis prohibition showed that the academic 
performance of students who were no longer legally 
permitted to buy cannabis increased substantially (Marie 
and Zölitz, 2015). Further analysis suggested that these 
performance gains were driven by improved understanding 
of material (cognitive ability) rather than changes in 
students’ study effort (motivation).
|  Are national parliaments discussing decriminalisation or legalisation?
No national government in the European Union has 
expressed any support for the idea of legalisation of 
cannabis for recreational use, but there have been 
discussions about reducing penalties for cannabis 
use-related offences. Members of national parliaments 
who are usually not in government have also proposed 
draft laws for cannabis legalisation.
Entities within at least four governing administrations have 
questioned their countries’ legal approach to penalising 
cannabis use-related offences, and considered the 
possibility of change.
In Belgium, in 2014, according to a report to the EMCDDA 
from the Reitox national focal point, an evaluation of the 
current cannabis policy was conducted by the General Drugs 
Policy Cell on the request of the Minister of Public Health in 
response to public and national and international debates 
about penalties for possession and use of cannabis. The 
evaluation concluded that the legal framework and guidelines 
for penalties on the possession of cannabis was complex, 
contained many technical flaws, and led to uncertainties for 
all involved. A clear, coherent and pragmatic legal framework 
was needed, but the legalisation of cannabis and its 
derivatives was incompatible with Belgium’s commitments to 
the United Nations and European Union. A technical report 
on a future policy is now being finalised by the General Drugs 
Policy Cell and the Inter-Ministerial Conference on Drugs, 
which coordinates cooperation between the state and the 
different federal policy levels.
In Ireland, a debate developed on whether to follow the 
Portuguese model and decriminalise the possession of all 
drugs, not just cannabis. After a public consultation, the 
cross-parliamentary Justice, Defence, and Equality 
Committee and the then minister for the national drugs 
strategy declared they supported the proposal (O’Keeffe, 
2015). The debate on this issue continues after a change in 
government.
In France, a parliamentary report on the evaluation of the 
fight against illicit drug use proposed to transform 
cannabis-use offences into third-class contraventions 
(punishable by a maximum fine of EUR 450) (Le Dain and 
Marcangeli, 2014). One of the two rapporteurs 
recommended legalising private cannabis use by adults 
and establishing a regulated supply of cannabis under the 
control of the state. In the framework of the draft law on 
health under discussion in 2015, the Senate approved an 
amendment to punish a first instance of drug use by 
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a third-class contravention. However, the government did 
not approve it, and in January 2016 the new health law 
was approved without this change.
In Italy, the 2014 Annual Report of the National Anti-Mafia 
Directorate concluded, after reviewing the national seizure 
and consumption statistics for cannabis, that it was 
neither feasible nor desirable, given resources required for 
other operations, to increase repressive actions, which 
were ‘objectively inadequate’ (Direzione Nazionale 
Antimafia, 2014). It invited lawmakers to reconsider 
existing policies for combating the sale and use of 
cannabis, and consider whether ‘depenalisation’ would 
better balance protecting the right to health of citizens 
against the use of law enforcement and criminal justice 
resources while reducing the criminal market.
National parliaments have also started to see detailed 
proposals for the legalisation of cannabis. These tend to be 
from political parties not in government, and so they are 
usually rejected. However, as these are proposals for 
fundamental change of the control system rather than 
simple adjustments, it may be useful to outline them in 
order to see the different control systems being put 
forward around Europe.
In Ireland, a private member’s bill in 2013 proposed 
a system of licensed cultivation (commercial, home, social 
club), distribution and sale. Retail sale would be limited to 
one ounce (28 grams) per transaction, with the product in 
plain packaging, while advertising would be limited to adult 
magazines and websites. Taxation revenue would be fully 
ring-fenced to be invested in addiction services, medical 
research on cannabis and juvenile education on drug-use 
issues. The bill was defeated by 111 votes to 8 on 
6 November 2013 (The Journal, 2013).
In Poland, draft legislation to amend the national drug law 
in order to permit cannabis clubs was presented to the 
parliament in 2013 as a bill from the party Ruch Palikota 
(Ruch Palikota, 2013). The draft was not taken further after 
the Legal Parliamentary Commission recognised that it 
was incompatible with international drug conventions and 
unconstitutional (the draft proposed responsibilities for 
the Ministry of Justice which were not delegated in line 
with constitutional requirements).
In Portugal, in June 2013, the national parliament debated 
a bill from the Left Bloc (Bloco de Esquerda), which aimed to 
legalise the cultivation of cannabis for personal use. It would 
permit possession of 30 days’ doses (defined like the current 
10-day limit for an administrative offence), cultivation of 
10 plants (Lusa, 2013) and allow the creation of clubs for 
cannabis consumption, with a maximum of 300 members. 
The bill was put to a formal vote but was not approved and 
nor was an amended version of the bill in April 2015.
In France, in January 2014, the ecologist group presented 
a legislative draft to regulate the production of cannabis 
products that could be sold through tobacconists without 
advertising, for use in private but not public spaces. 
It prohibited sale to minors and sales by vending machines 
(France Info, 2015). After various hearings and 
amendments, the bill was rejected in April 2015.
In the Netherlands, a private member’s bill was proposed 
on 26 February 2015 by two members of the political party 
D66. This draft law had two aims. The first was to give legal 
force to the existing coffeeshop tolerance criteria by 
embedding them into the Opium Act itself, rather than the 
accompanying Directive as at present; within this, the 
maximum stock level that is currently 500 grams could be 
changed by each municipality. The second aim was to 
create a regulated system of cultivation and supply for the 
sale of cannabis in coffeeshops, to counter the organised 
crime that currently occupies this role and the associated 
dangers of illegal cultivation such as nuisance and fire. 
Professional growers would be licensed and responsible 
for product quality and packaging.
In Germany, a draft cannabis control act was presented to 
the German Bundestag by the parliamentary group of 
Bündnis90/Greens in March 2015 and referred to the 
relevant committees for consultation. It would legalise 
possession of 30 grams of cannabis (herb or resin) or three 
female plants and licence growers and specialist sales 
outlets. The product would be taxed at EUR 4/gram for herb, 
EUR 5 for resin and EUR 6 for oils. In May 2015 two members 
of parliament, from the (governing) conservative party CDU 
and the (in opposition) Green Party, published a position 
paper proposing the legalisation of cannabis in order to gain 
EUR 2 billion in taxes instead of spending EUR 2 billion on 
prosecuting cannabis users (Mayer-Rüth, 2015; Waters, 
2015). As yet, no legal changes have been made.
In Italy, on 24 November 2015, 221 members of parliament 
presented a draft law (PDL n.3447) to legalise cannabis 
cultivation and sale which received cross-party support. 
The bill proposed a state monopoly on cultivation and sale 
while allowing registered citizens to grow five female 
plants. Citizens would be permitted to carry 5 grams of 
cannabis product or possess 15 grams in a private home. 
It also allowed non-profit cannabis growers’ clubs with 
a maximum of 50 members (thus 250 plants). As at 
January 2017, following examination by the Joint 
Parliamentary Commission on Justice and Social Affairs, 
the bill was being examined in several parliamentary 
commissions where many amendments were tabled.
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In Norway, in 2015, the Green Party came out in favour of 
legalisation of cannabis, with strict regulation, to protect 
the consumers and the community generally (MDG, 2015).
In Slovenia, at the beginning of 2016, the Social 
Democratic party, a member of the governing coalition, 
proposed two variants of a draft law on cannabis. In the 
first variant, personal cannabis cultivation and collective 
cultivation (social clubs) would be permitted under licence; 
in the second variant these would not be permitted, and 
cannabis cultivation would only be allowed by licensed 
producers. Retail would only be through pharmacies, and 
the limits to recreational cannabis would be possession of 
10 grams of products per day of up to 20 % THC (limits for 
medical cannabis would be higher).
|  How much support is there for legalisation of cannabis around Europe?
There are few comparable surveys that indicate whether 
there is any interest in legalisation of cannabis across the 
European Union. Two possible indicators, the 
Eurobarometer opinion surveys of young people and the 
citizens’ initiative aimed at the European Commission, 
suggested that there was little support for Europe-wide 
legalisation. Within countries, non-parliamentary 
expressions of support have been seen in citizens’ 
initiatives that ask national governments to change and 
local or regional initiatives.
The opinions of young Europeans on a wide range of topics 
are sampled regularly by the ‘Flash Eurobarometer’ (FEB) 
poll. On the three occasions the survey has asked a small 
sample of 15- to 24-year-olds in each country around 
Europe their opinion on whether cannabis sale should be 
banned or regulated, it has found that the majority of this 
young age group support the ban. However, the size of the 
majority has been falling over time, from 67 % in 2008 
(FEB 233), to 59 % in 2011 (FEB 330) and 53 % in 2014 
(FEB 401) (European Commission, 2014).
A citizens’ petition to the European Commission was 
initiated via the European Citizens’ Initiative register in 
2013 to request a common European policy on regulated 
cannabis production, sale and use. It only received 
approximately 173 000 signatures, rather than the one 
million required for further consideration, before it was 
closed in 2015.
Several national parliamentary or government websites in 
Europe provide for citizens to start petitions; if a petition 
receives enough signatures by a certain deadline, the 
legislature is required to consider it officially and respond. 
Citizens’ petitions on cannabis laws are summarised in 
Table 3.
TABLE 3
Citizen petitions in the European Union to change cannabis laws
Country Change desired Petitioners
Year 
considered
Outcome
Slovenia Legalise home growing of cannabis for 
medical and personal use
11 000 2014 Government moved THC from 
Group I to Group II in the law
Latvia (The Baltic 
Times, 2015)
Remove all penalties for growing, possessing 
and carrying small amounts of cannabis and 
use in private
10 000+ 2015 Rejected by parliament
European 
Commission
A common European policy on regulated 
cannabis production, sale and use
173 000 2015 Insufficient petitioners; closed
Austria (Parliament of 
Austrian Republic, 
2015)
Legalise growing and producing cannabis for 
personal use, purchase/possession of small 
quantities for persons aged over 16
32 000 2015 Amendment to Narcotic Substances 
Act asks police to report non-
problematic users to health 
authorities, not judicial authorities (1)
United Kingdom 
(Petitions: UK 
Government and 
Parliament, 2015)
Legalise production, sale and use of cannabis 235 000 2015 Parliament rejected
Estonia (ERR, 2015) Legalise recreational use of cannabis 5000 2016 Discussed in Parliament Legal 
Affairs Committee; ongoing
(1) Reportedly this was quite likely even without the petition.
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Although most of these petitions achieved the level of 
support required for further consideration, no government 
has yet agreed to make the proposed legislative change.
On 18 March 2016, a draft law on legal regulation of 
cannabis and derivatives production, consumption and 
trade was presented in Italy as a ‘popular initiative’ (Pini, 
2016). Within the 6-month deadline, 57 500 signatures 
were collected (more than the requirement of 50 000), and 
so they were presented to the Chamber of Deputies on 
11 November 2016. By January 2017, the text had not yet 
been included in a parliamentary session. It provides, 
among other things, freedom of individual self-cultivation 
or associated production in ‘cannabis social clubs’, the 
widest possible access to medical cannabis, an annual 
report to the parliament, the total ‘depenalisation’ of 
personal use of all substances, and the release of 
prisoners held for conduct not criminally punishable.
There have also been expressions of interest in changing 
cannabis legislation at a regional or city level, as these 
examples from four different countries show.
In Spain, in 2012, the Basque Parliament discussed 
possible solutions to the growing activity of cannabis social 
clubs. In 2014, the city of San Sebastian in the Basque 
country passed regulations that would limit the clubs’ 
opening hours and proximity to schools (Fanals, 2014), and 
the Catalan city of Girona passed a Special Urbanism Plan 
on the clubs in April 2015. In December 2014, the 
Parliament of Navarra also passed legislation to regulate 
cannabis social clubs. However, the Spanish government 
considered that these regulations and laws exceed the city 
and regional powers, and the Spanish Constitutional Court 
ordered their suspension in March 2015.
In Denmark, the Copenhagen city council has repeatedly 
made proposals to run a pilot project on the legal 
production, distribution and possession of cannabis, in 
order to take the cannabis business away from organised 
crime and reduce access to minors (CPH Post, 2013). 
These requests have been refused by the Danish ministers 
of justice and health because of the likelihood of increased 
harm to public health. The latest rejection was in March 
2014 (The Local, 2016).
Similarly, in Germany, the Kreuzberg-Friedrichshain district 
of Berlin submitted plans for four licensed ‘specialist 
cannabis shops’ in June 2015. These were rejected in 
October 2015 by the Federal Institute of Pharmaceuticals 
(BfArM) (The Local, 2015).
In the Netherlands, in May 2015, the lower house of 
parliament voted by a narrow majority against any form of 
regulating cannabis cultivation. In November 2015, 
a commission of the Union of Municipalities (VNG) 
published a report calling on the government to regulate 
small-scale, localised cannabis cultivation in order to take 
the cannabis business away from organised crime 
(DutchNews, 2015). At the annual general meeting of the 
VNG, almost 90 % of the municipalities present voted in 
favour of a proposal to urge the national government to 
start experiments regarding the legal regulation of 
cannabis cultivation and sale.
In addition to these societal, political or local calls for 
change, there have also been some proposals from the 
more intellectual spheres, such as the conservative journal 
Minerva (linked to the think-tank Civita) in Norway 
(Minerva, 2011) and ‘Terra Nova’ in France (Ben Lakhdar et 
al., 2014). In Belgium, some professors have argued for 
a critical evaluation of the country’s cannabis policy (KU 
Leuven, 2013), while others have advocated for regulation 
at European and global level, arguing that no single country 
can successfully act in isolation (Fijnaut and De Ruyver, 
2015). In Germany, 120 law professors also argued that 
cannabis should be legalised in order to stop mass 
criminalisation, to run better prevention campaigns and to 
regulate the quality of the product for users’ safety 
(Bleiker, 2014).
None of the initiatives listed above has yet resulted in any 
EU country significantly changing its laws on cannabis. 
There remain vocal sections of administrations and the 
general population in several countries that are pressing 
for, at the very least, a reduction in punishment for 
cannabis use-related offences.
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| Conclusion
This overview of the different approaches to cannabis 
legislation in Europe has surveyed the complexities and 
the similarities of the laws across the Member States of 
the European Union, Norway and Turkey.
It is not easy to discern a common approach to the 
legislation surrounding cannabis across these countries. 
Many countries differentiate the legislation and penalties 
around cannabis sale and use, but in different ways. 
Several countries treat all illicit drugs the same in the laws, 
others define cannabis offences as a less serious legal 
matter, and a few prescribe more severe penalties for 
cannabis offences.
In some European countries, data suggest a tendency for 
police to formally register cannabis users, rather than 
overlook them due to prioritisation of other offences. 
Despite differences in formal legal sanctions, in most EU 
countries the actual penalties for possession and use (and 
often supply) of cannabis are often less severe than those 
for other illicit substances. Where countries have sought to 
divert cannabis users into treatment, it is not evident that 
this approach has received widespread support, with 
legislative initiatives being designed and implemented 
with varying degrees of enthusiasm. It is not clear how 
much this is based on a desire to prioritise a punitive 
approach or a lack of confidence in the effectiveness of 
more rehabilitative responses.
Over the last 20 years, at least 15 European countries have 
made changes to their legislation affecting penalties for 
cannabis users, though there has been little rigorous 
scientific evaluation of these. It is unclear whether 
increasing or reducing legal penalties for cannabis use 
offences has had a clear or consistent effect on levels of 
cannabis use in any of these countries. The practical 
application of the legislation may be varied according to 
directives or discretion, and effects may also vary 
according to the users’ perception of the penalties that 
they could receive. Use rates may be affected by other 
factors, such as anti-smoking policies, and other 
environmental prevention strategies may also be playing 
a role.
Attempts to develop systems where supply of recreational 
cannabis is not punished, such as coffeeshops in the 
Netherlands and cannabis social clubs, have made little 
progress. There are fewer coffeeshops in the Netherlands 
than there were 15 years ago, and they are more tightly 
controlled. Despite interest in cannabis social clubs in 
a number of European countries, none has yet achieved 
even a ‘semi-legal’ status in which its operation is tolerated 
but not condoned. In a more global context, European 
countries have not sought to legalise recreational cannabis 
in the way that is happening in Uruguay and an increasing 
number of US states. The few countries that have 
developed systems to legally produce and distribute 
cannabis for medical purposes ensure they are strictly 
regulated. No country permits the supply or possession of 
medical cannabis without a doctor’s prescription and the 
cannabis that is provided for medical use is cultivated 
under government supervision.
This overview is published at a time of mounting public 
debate about cannabis policy. On the one hand, advocates 
for change claim that cannabis is less harmful than other 
drugs. They point to legalisation of recreational cannabis in 
several US states and Uruguay, and upcoming legalisation 
in Canada. On the other hand, European statistics show 
the increasing potency of illicit cannabis and the increasing 
number of people seeking treatment for their cannabis 
use. Academics and others question the rationale for 
individual countries’ legal approaches to cannabis and 
advocate a scientific evaluation of the impact of current 
legislation. Matters are further complicated, as several 
advocates and commentators conflate medical and 
recreational cannabis. However, while there are vocal 
requests to change national and even local policies 
towards recreational use of cannabis, there is little 
evidence that these proposals receive majority public 
support.
During this time of debate and evolution of the legislative 
situation around Europe and beyond, the EMCDDA will 
continue to monitor developments in cannabis use and 
cannabis control. When discussions take place among 
policymakers, it is hoped that this brief picture of the laws 
of cannabis use and supply around Europe will provide an 
objective and reliable basis for future policy decisions.
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■■ Cannabis control in Europe
■■ Cannabis production and markets in Europe
■■ Annual reports on the drug problem in Europe and European drug reports
■■ European drug markets report (EMCDDA and Europol)
■■ Illicit drug use in the European Union — legislative approaches
■■ Findings from the DRUID project
■■ Models for the legal supply of cannabis
■■ Characteristics of frequent and high-risk cannabis users
■■ Drug offences: sentencing and other outcomes
■■ European legal database on drugs
EMCDDA publications are available online from the agency’s website (http://emcdda.
europa.eu/publications).
Other sources include reports from the Reitox network of national focal points, the Legal 
and Policy Correspondents network and the European Commission.
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About this publication
At a time of increased debate on the laws controlling 
the use of cannabis in the European Union, this report 
answers some of the questions most often asked about 
cannabis legislation. Using a question and answer 
format, basic definitions and the obligations of 
countries under international law are set out in 
a section on ‘What is cannabis and what are countries’ 
obligations to control it?‘ Two following sections 
examine the links and disparities between the content 
of the laws and their guidelines on the one hand and 
the actual implementation of the laws on the other. The 
final question and answer section considers whether 
changes in law have affected cannabis use and how 
much public support for legal change exists, as it looks 
at the future direction of cannabis legislation in Europe.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level. The EMCDDA’s 
publications are a prime source of information for 
a wide range of audiences including: policymakers and 
their advisors; professionals and researchers working in 
the drugs field; and, more broadly, the media and 
general public. Based in Lisbon, the EMCDDA is one of 
the decentralised agencies of the European Union.
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